VALENTINE'S DAY in San Diego this year dawned cold and grim for Saundra Pelletier. It should have been a day of celebration-or at least marketing synergy-for the CEO of Evofem Biosciences, a women's health company with an unapologetically sex-positive mission. Its first and only product is a contraceptive gel called Phexxi, which Evofem markets to the millions of women eager for a birth control option without hormones. More than 100,000 people have gotten a prescription for Phexxi since it launched in late 2020; millions more have watched its $30 million viral commercial, starring Schitt's Creek comedian Annie Murphy.
But the past few years have stretched Pelletier's company to its limits. Evofem more than tripled its sales last year, to $16.7 million in the first nine months of 2022-but it lost $68.4 million over that same period and is carrying $84 million of debt. A crucial clinical trial failed in October, dooming Pelletier's efforts to expand Phexxi's market. Now some patients are casting doubt on Phexxi's basic effectiveness, claiming in online reviews that they have gotten pregnant while using the gel.
Some of these problems are of Evofem's own making. But the worst body blows-to Evofem, and to the other companies trying to serve the 47 million U.S. women who use contraception-have come from the broken health care system. Investors and large pharma companies have largely abandoned the women's health field, leaving the development of new contraceptives to small, scrappy specialists like Evofem, Agile Therapeutics, and TherapeuticsMD. But companies that have won approval for their products have quickly discovered that most big insurance companies would not pay for them, despite a federal law requiring them to do so.
Bu hikaye Fortune US dergisinin April - May 2023 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye Fortune US dergisinin April - May 2023 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Giriş Yap
AI Isn't Coming for Your Job At Least Not Yet
So far, the technology has replaced only a small number of workers. But the future risks many more.
THE TRUTH EVEN HE CAN'T DUCK
Aflac's DAN AMOS has spent his 34 years as CEO selling insurance against illness and death. Now he has to confront his aging customers' mortality and his own.
THE NEW HOLLYWOOD POWER PARADIGM
Inside the sisterhood of stars changing the narrative.
SAUDI ARABIA'S POWER PIPELINE
The oil earnings flowing from the most profitable company in history are helping the Saudi kingdom shake up the global economyand the old geopolitical order.
THE [FOREVER] FOUNDER
Michael Dell turned his dorm-room PC company into the go-to hardware provider for 99% of the Fortune 500. Now the longest-standing founder-CEO in tech has a chance to cash in on the AI bbom—and make himself and his company bigger than ever.
HOW BOEING BROKE DOWN
Boeing's strategy sent the stock soaring more than 1,000% over 20 years. But it contained dangerous flaws that are only now coming into view amid a drumbeat of terrible news.
The Art of Banking
To appeal to the ultrawealthy, banks like UBS keep fine art-and art expertsclose at hand.
Is the Bitcoin Bull Market Safe to Buy?
ETFs have made Bitcoin investing easier than ever. But they may be adding air to a bubble.
Goodbye, Tough Guy
More executives are going on all-male retreats to open up, feel less lonely, and build empathy.
Memo to Silicon Valley: Bring It On
New York City's Runway was the pioneering leader in Al-generated video for years. Now ChatGPT maker OpenAl is coming for it.